(Q34092425)

English

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study (English)

1 reference

Europe PubMed Central

31 July 2017

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Costantino Pitzalis

object named as

Costantino Pitzalis

10

0 references

author name string

Mark C Genovese

1

1 reference

Europe PubMed Central

31 July 2017

Roy Fleischmann

2

1 reference

Europe PubMed Central

31 July 2017

Daniel Furst

3

1 reference

Europe PubMed Central

31 July 2017

Namieta Janssen

4

1 reference

Europe PubMed Central

31 July 2017

John Carter

5

1 reference

Europe PubMed Central

31 July 2017

Bhaskar Dasgupta

6

1 reference

Europe PubMed Central

31 July 2017

Judy Bryson

7

1 reference

Europe PubMed Central

31 July 2017

Benjamin Duncan

8

1 reference

Europe PubMed Central

31 July 2017

Wei Zhu

9

1 reference

Europe PubMed Central

31 July 2017

Patrick Durez

11

1 reference

Europe PubMed Central

31 July 2017

Kosmas Kretsos

12

1 reference

Europe PubMed Central

31 July 2017

language of work or name

0 references

publication date

18 March 2014

1 reference

Europe PubMed Central

31 July 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

31 July 2017

73

1 reference

Europe PubMed Central

31 July 2017

9

1 reference

Europe PubMed Central

31 July 2017

1607-1615

1 reference

Europe PubMed Central

31 July 2017

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

The role of interleukin 6 in the pathophysiology of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, rad

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Cytokines in the pathogenesis of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4145439

5 July 2018

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204760

21 January 2018

Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2013-204760

21 January 2018

Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/24641941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24641941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic criteria in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24641941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/24641941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24641941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24641941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24641941

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2013-204760

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34092425&oldid=1539677921"